RxDoctor Payments Data

Monica Vandivort, MD

Geriatric Medicine · Sierra Vista, AZNPI 1720044365

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 8 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by Aimmune Therapeutics, Inc. at 25.1% of the total. 2024 is the largest year on record at $107, 6.4 times the $17 reported in 2021. That places this record below the midpoint for geriatric medicine clinicians in AZ, where the typical reported total is $138.

$152in general payments, 2019–2025

Across 8 payments — averaging $18.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Aimmune Therapeutics, Inc.$38
  • Novartis$30
  • Bayer$25
  • Alkermes, Inc.$17
  • Exact Sciences$15
  • Collegium Pharmaceutical, Inc.$14
  • plus $13 from 1 others

What the payments were for

  • Food & beverage$152100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$152 in reported general payments places this provider in the 50th percentile of 75 geriatric medicine providers in Arizona.

See all geriatric medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$82,127
Medicare patients
208
Services billed
797

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban229$79,104
TrulicityDulaglutide79$74,279
JardianceEmpagliflozin91$32,983
XareltoRivaroxaban81$32,267
CreonLipase/Protease/Amylase50$22,550
OzempicSemaglutide22$22,484
Duloxetine Hcl308$18,953
MounjaroTirzepatide17$17,422
MyrbetriqMirabegron39$14,839
EntrestoSacubitril/Valsartan30$13,844
JanuviaSitagliptin Phosphate41$12,842
LinzessLinaclotide19$12,662
BelsomraSuvorexant38$12,655
Pantoprazole Sodium195$12,579
Gabapentin404$11,566

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$13$91,70196 claims
NovartisEntresto$30$13,84430 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 75 geriatric medicine providers in Arizona.

Other geriatric medicine in Sierra Vista

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →